

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab)

Recombinant Antibody
Catalog # APR10097

Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P32970
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	21118

Additional Information


Target/Specificity	TNFSF7 / CD27L / CD70
Endotoxin Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Protein Information


Name	CD70 (HGNC:11937)
Function	Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells (PubMed: 28011863 , PubMed: 28011864 , PubMed: 8387892). The CD70- CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells (PubMed: 28011863 , PubMed: 28011864).
Cellular Location	Cell membrane; Single-pass type II membrane protein

Images


Anti-TNFSF7 / CD27L / CD70 Reference Antibody
(vorsetuzumab) on SDS-PAGE under reducing (R)
condition. The gel was stained with Coomassie Blue. The




purity of the protein is greater than 95%



The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) is more than 99.29% ,determined by SEC-HPLC.



HL-60 cells were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC150=0.06731 ug/mL



The endocytosis ratio vorsetuzumab by 786-O increased with the increase of antibody concentration, and the Internalization Rate (%) reached 55% at antibody concentration of 0.67 nM.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.